CDK4/6 inhibition in luminal breast cancer

被引：10

作者：

Gampenrieder S.P. ^{[1
,2
,3
]}

Rinnerthaler G. ^{[1
,2
,3
]}

Greil R. ^{[1
,2
,3
]}

机构：

[1] IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, Salzburg

[2] Laboratory of Immunological and Molecular Cancer Research, Center for Clinical Cancer and Immunology Trials, Salzburg Cancer Research Institute, Salzburg

[3] Cancer Cluster Salzburg, Salzburg

来源：

memo - Magazine of European Medical Oncology | 2016年 / 9卷 / 2期

关键词：

Abemaciclib; CDK4/6; inhibitors; Endocrine resistance; Palbociclib; Ribociclib;

D O I：

10.1007/s12254-016-0268-2

中图分类号：

学科分类号：

摘要：

Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combination strategies of endocrine therapy with targeted agents are aimed to overcome endocrine resistance. The selective CDK4/6 inhibitor palbociclib has shown promising results in metastatic luminal breast cancer when used in combination with endocrine therapy both in the first-line setting as in pretreated women. The drug showed a manageable safety profile with uncomplicated neutropenia as the most frequent side effect. Approval was already granted in the US and is also awaited during 2016 for Europe. © 2016, The Author(s).

引用

页码：76 / 81

页数：5

共 20 条

[1]

Hanahan D., Weinberg R.A., Hallmarks of cancer: the next generation, Cell, 144, 5, pp. 646-674, (2011)

[2]

Cancer Genome Atlas, Comprehensive molecular portraits of human breast tumours, Nature, 490, 7418, pp. 61-70, (2012)

[3]

Cicenas J., Valius M., The CDK inhibitors in cancer research and therapy, J Cancer Res Clin Oncol, 137, 10, pp. 1409-1418, (2011)

[4]

Finn R.S., Et al., The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 16, 1, pp. 25-35, (2015)

[5]

Turner N.C., Et al., Palbociclib in hormone-receptor-positive advanced breast cancer, N Engl J Med, 373, 3, pp. 209-219, (2015)

[6]

Knudsen E.S., Knudsen K.E., Tailoring to RB: tumour suppressor status and therapeutic response, Nat Rev Cancer, 8, 9, pp. 714-724, (2008)

[7]

Asghar U., Et al., The history and future of targeting cyclin-dependent kinases in cancer therapy, Nat Rev Drug Discov, 14, 2, pp. 130-146, (2015)

[8]

Witkiewicz A.K., Knudsen E.S., Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions, Breast Cancer Res, 16, 3, (2014)

[9]

Lange C.A., Yee D., Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer, Endocr Relat Cancer, 18, 4, pp. C19-C24, (2011)

[10]

Ma C.X., Et al., Mechanisms of aromatase inhibitor resistance, Nat Rev Cancer, 15, 5, pp. 261-275, (2015)

← 1 2 →